Resistance to Afatinib and Cetuximab Combination Therapy in EGFR-mutant Lung Adenocarcinomas

被引：0
|
作者：
Pirazzoli, Valentina
Takezawa, Ken
de Stanchina, Elisa
Pao, William
Politi, Katerina
机构：
来源：
CLINICAL CANCER RESEARCH | 2012年 / 18卷 / 10期
关键词：
D O I：
10.1158/1078-0432.MECHRES-A38
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A38
引用
下载
收藏
页数：2
相关论文
共 50 条
  • [1] Acquired Resistance of EGFR-Mutant Lung Adenocarcinomas to Afatinib plus Cetuximab Is Associated with Activation of mTORC1
    Pirazzoli, Valentina
    Nebhan, Caroline
    Song, Xiaoling
    Wurtz, Anna
    Walther, Zenta
    Cai, Guoping
    Zhao, Zhongming
    Jia, Peilin
    de Stanchina, Elisa
    Shapiro, Erik M.
    Gale, Molly
    Yin, Ruonan
    Horn, Leora
    Carbone, David P.
    Stephens, Philip J.
    Miller, Vincent
    Gettinger, Scott
    Pao, William
    Politi, Katerina
    CELL REPORTS, 2014, 7 (04): : 999 - 1008
  • [2] Combination of afatinib with cetuximab in patients with EGFR-mutant non-small-cell lung cancer resistant to EGFR inhibitors
    Gomes, Jessica Ribeiro
    Cruz, Marcelo Rocha S.
    ONCOTARGETS AND THERAPY, 2015, 8 : 1137 - 1142
  • [3] Afatinib—new therapy option for EGFR-mutant lung cancer
    Helena A. Yu
    William Pao
    Nature Reviews Clinical Oncology, 2013, 10 : 551 - 552
  • [4] Afatinib monotherapy in EGFR-mutant lung adenocarcinoma
    Gilbert, Judith A.
    LANCET ONCOLOGY, 2013, 14 (09): : E345 - E345
  • [5] Dramatic Response to Afatinib in EGFR-Mutant Lung Adenocarcinomas After Resistance to First-Generation EGFR Inhibitors: A Brief Report
    Li, W.
    Yang, J.
    Chen, H.
    Li, A.
    Lin, J.
    Tu, H.
    Su, J.
    Zhang, X.
    Wu, Y.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2221 - S2221
  • [6] Afatinib plus Cetuximab First-line in EGFR-Mutant Lung Cancer-Letter
    Cortot, Alexis B.
    Moro-Sibilot, Denis
    Cadranel, Jacques
    CLINICAL CANCER RESEARCH, 2016, 22 (07) : 1827 - 1827
  • [7] Brief Report: Combination of Osimertinib and Dacomitinib to Mitigate Primary and Acquired Resistance in EGFR-Mutant Lung Adenocarcinomas
    Elkrief, Arielle
    Makhnin, Alex
    Moses, Khadeja A.
    Ahn, Linda S.
    Preeshagul, Isabel R.
    Iqbal, Afsheen N.
    Hayes, Sara A.
    Plodkowski, Andrew J.
    Paik, Paul K.
    Ladanyi, Marc
    Kris, Mark G.
    Riely, Gregory J.
    Michor, Franziska
    Yu, Helena A.
    CLINICAL CANCER RESEARCH, 2023, 29 (08) : 1423 - 1428
  • [8] Overcoming therapy resistance in EGFR-mutant lung cancer
    Antonio Passaro
    Pasi A. Jänne
    Tony Mok
    Solange Peters
    Nature Cancer, 2021, 2 : 377 - 391
  • [9] Overcoming therapy resistance in EGFR-mutant lung cancer
    Passaro, Antonio
    Janne, Pasi A.
    Mok, Tony
    Peters, Solange
    NATURE CANCER, 2021, 2 (04) : 377 - 391
  • [10] Acquired resistance to afatinib plus cetuximab in EGFR-mutant lung adenocarcinoma may be mediated by EGFR overexpression and overcome by the mutant-specific EGFR inhibitor, AZD9291.
    Meador, Catherine B.
    Jin, Hailing
    de Stanchina, Elisa
    Pirazzoli, Valentina
    Ladanyi, Marc
    Wang, Lu
    Chen, Xi
    Eisenberg, Rosana
    Cross, Darren
    Pao, William
    CLINICAL CANCER RESEARCH, 2014, 20
12345